Sanofi-Aventis will pay $95.5 million to settle allegations that it overcharged state Medicaid programs for anti-inflammatory nasal sprays, the Justice Department announced Thursday.
The settlement resolves charges that between 1995 and 2000 Aventis Pharmaceutical Inc. knowingly misreported its best drug prices to Medicaid programs. Under U.S. law, drug makers are required to report to the government the best prices for their drugs and give those rates to Medicaid.
The Justice Department said Aventis manipulated its "best price" numbers for the nasal sprays by entering into an agreement with the HMO Kaiser Permanente that repackaged Aventis' drugs under a new label.
More at WSJ
No comments:
Post a Comment